Trial Profile
Prospective observational study on efficacy and safety of PEGASYS/COPEGUS for the treatment of CHC patients with compensated LC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 05 Sep 2011 New trial record